Casein kinase 2 subunit alpha mRNA (CK2 mRNA)

Casein kinase 2 (CK2) mRNA refers to the messenger RNA transcript encoding the catalytic alpha subunit (CSNK2A1) of the CK2 enzyme, a highly conserved and constitutively active serine/threonine kinase [1]. CK2 is a master regulator of cellular homeostasis, influencing critical pathways such as PI3K/Akt/mTOR, Wnt, and NF-kappaB, and is essential for DNA damage repair and cell cycle progression [2]. In many human cancers, CK2 is significantly overexpressed, which suppresses apoptosis and facilitates the survival of malignant cells under stress conditions [3]. Therapeutic targeting of CK2 mRNA via RNA interference (siRNA) or antisense oligonucleotides (ASOs) aims to downregulate the expression of the kinase, thereby inhibiting its oncogenic signaling and sensitizing tumor cells to chemotherapy [4]. While small molecule inhibitors like Silmitasertib (CX-4945) are currently in clinical trials for their ability to block the protein's catalytic activity, mRNA-targeted strategies offer the potential advantage of depleting the protein entirely, which may be necessary to overcome the kinase's extensive network of protein-protein interactions [5]. Additionally, CK2 has been identified as a critical host factor for viral replication, including SARS-CoV-2, making its mRNA a potential target for antiviral intervention [6].

Other names

CSNK2A1 mRNACK2A1 mRNACasein kinase II alpha mRNACK2 alpha mRNACasein kinase 2 catalytic subunit alpha mRNA

RNA interference (siRNA) and antisense inhibition (ASO) leading to the degradation of the mRNA transcript and subsequent reduction in Casein kinase 2 protein expression.